Clinical Trial Update: OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC [Phase 2]

View source ↗

Summary

This entry describes a Phase 2 trial evaluating OSE2101 with FOLFIRI, or FOLFIRI maintenance after FOLFIRINOX induction, in advanced or metastatic pancreatic du…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FOLFIRI (irinotecan, leucovorin, 5-fluorouracil)
• OSE2101

Snippet

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group | Conditions: Pancreatic Ductal Adenocarcinoma, Locally Advanced Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING